GlassScriptPhysician profile
Vanessa Isiaka
NPI 1316336969
$4,061.00
in general payments reported to CMS, 2019-2025
36 companies · $523 in 2025
The $523 reported for 2025 was more than what 81% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $994 · 2020: $428 · 2021: $976 · 2022: $413 · 2023: $329 · 2024: $398 · 2025: $523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,237 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,237.05 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,196.15 | 2019-2024 | |
| Pfizer INC. | $272.41 | 2021-2025 | |
| Amag Pharmaceuticals, INC. | $246.52 | 2019-2020 | |
| Exeltis, USA INC. | $206.05 | 2019-2025 | Slynd |
| Allergan, INC. | $196.78 | 2019-2020 | |
| Therapeuticsmd, INC. | $161.04 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $147.39 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $140.67 | 2021-2025 | |
| Astellas Pharma US INC | $130.83 | 2023-2025 | Veozah |
| Millicent US INC | $113.32 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Sumitomo Pharma America, INC. | $111.98 | 2023-2025 | Myfembree |
| Evofem Biosciences, INC. | $111.31 | 2021-2025 | Solosec, Phexx, Phexxi |
| Hologic Sales and Service, LLC | $103.14 | 2019-2024 | Acessa Provu System |
| Sage Therapeutics, LLC | $90.51 | 2025 | Zurzuvae |
| Ethicon US, LLC | $80.09 | 2019-2024 | Enseal |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $77.13 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $76.40 | 2019-2025 | Gardasil 9 |
| Radius Health, INC. | $61.11 | 2019 | |
| Myovant Sciences INC. | $59.79 | 2021-2022 | |
| Baxter Healthcare | $46.93 | 2022-2025 | Perclot |
| Mallinckrodt Enterprises LLC | $37.84 | 2019 | |
| Zyla Life Sciences, INC. | $35.52 | 2020 | |
| Mission Pharmacal Company | $35.16 | 2019-2021 | |
| Organon LLC | $34.68 | 2021-2022 | |
| Agile Therapeutics, INC. | $34.06 | 2021-2022 | |
| Lupin INC. | $33.22 | 2019 | |
| Aspira Women'S Health INC | $30.19 | 2022 | |
| Meditrina | $25.99 | 2024 | |
| Vertical Pharmaceuticals, LLC | $25.61 | 2019 | |
| Becton, Dickinson and Company | $25.56 | 2024 | Bd Onclarity |
| Supernus Pharmaceuticals, INC. | $25.40 | 2025 | Qelbree |
| Duchesnay USA Incorporated | $20.93 | 2019 | |
| Roche Diagnostics Corporation | $20.00 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.90 | 2022 | |
| Exact Sciences Corporation | $15.18 | 2025 | The Cologuard Plus Collection Kit |
| Avion Pharmaceuticals | $13.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanessa Isiaka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.